KAT2B and renal cell carcinoma: Mechanistically, in renal cell carcinoma, the abundance of ROS inhibits the P300/CBP-associated factor (PCAF)-dependent acetylation of PKM2 the lysine residue 305 site (K305), contributing to ETOP resistance (Shanmugasundaram et al. 2017).